Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Q3 Revenues Double, Losses Narrow

NEW YORK, Oct. 22 (GenomeWeb News) – Luminex today reported increased net revenues for the third quarter, and significantly narrowed net losses.

The Austin, Texas company, which makes the xMap bead assay system for genomics and proteomics research and other applications, reported revenues of $7.2 million for the quarter, compared to $3.6 million for the third quarter of 2002. Net losses for the quarter came to $.9 million, compared to $5.8 million for the same period last year.

The company's R&D expenses decreased to $.7 million, from $1.2 million for the year-ago period.

As of Sept. 30, Luminex had $40.2 million in cash and cash equivalents.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.